Following recent data, ATAGI recommends that severely immunocompromised children between the ages of 5 to 11 years receive a 3rd primary dose of the COVID-19 vaccine to optimise their protection against COVID-19 infection.
Current data has not identified any concerning safety signals in this cohort. ATAGI continues to review and closely monitor reports regarding the safety and efficacy of the COVID-19 vaccine in this age group.
This statement provides a concise summary of the January ATAGI meeting, including the latest recommendations and considerations regarding the safety and efficacy of the COVID-19 vaccine in children ages 5 to 11 years.
पूरा बयान पढ़ने के लिए नीचे दिए गए लिंक का अनुसरण करें:
ATAGI update following weekly COVID-19 meeting – 12 January 2022